Quantifying low-frequency revertants in oral poliovirus vaccine using next generation sequencing

- n.472U > C mutation must be closely monitored during OPV production to ensure safety.
- MAPREC, widely used to monitor 472-C revertants, requires radioisotope labeling.
- Next generation sequencing (NGS) has been proposed to replace MAPREC
- NGS performance was statistically equivalent to MAPREC for quantifying 472-C.
- NGS may be a useful alternative to MAPREC to monitor 472-C revertants in OPV lots.

Spontaneous reversion to neurovirulence of live attenuated oral poliovirus vaccine (OPV) serotype 3 (chiefly involving the n.472U > C mutation), must be monitored during production to ensure vaccine safety and consistency. Mutant analysis by polymerase chain reaction and restriction enzyme cleavage (MAPREC) has long been endorsed by the World Health Organization as the preferred in vitro test for this purpose; however, it requires radiolabeling, which is no longer supported by many laboratories. We evaluated the performance and suitability of next generation sequencing (NGS) as an alternative to MAPREC.The linearity of NGS was demonstrated at revertant concentrations equivalent to the study range of 0.25%-1.5%. NGS repeatability and intermediate precision were comparable across all tested samples, and NGS was highly reproducible, irrespective of sequencing platform or analysis software used. NGS was performed on OPV serotype 3 working seed lots and monovalent bulks (n = 21) that were previously tested using MAPREC, and which covered the representative range of vaccine production. Percentages of 472-C revertants identified by NGS and MAPREC were comparable and highly correlated (r ≥ 0.80), with a Pearson correlation coefficient of 0.95585 (p < 0.0001). NGS demonstrated statistically equivalent performance to that of MAPREC for quantifying low-frequency OPV serotype 3 revertants, and offers a valid alternative to MAPREC.